key: cord-0692883-l5tbyhe4 authors: Sotoodeh Ghorbani, Sahar; Taherpour, Niloufar; Bayat, Sahar; Ghajari, Hadis; Mohseni, Parisa; Hashemi Nazari, Seyed Saeed title: Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID‐19: A systematic review and meta‐analysis date: 2021-08-27 journal: J Med Virol DOI: 10.1002/jmv.27281 sha: 8e6581063ee9b724cb42ca29f38744667b6f23c5 doc_id: 692883 cord_uid: l5tbyhe4 Recent studies reported that some recovered COVID‐19 patients have tested positive for virus nucleic acid again. A systematic search was performed in Web of Science, PubMed, Scopus, and Google Scholar up to March 6, 2021. The pooled estimation of reinfection, recurrence, and hospital readmission among recovered COVID‐19 patients was 3, 133, and 75 per 1000 patients, respectively. The overall estimation of reinfection among males compared to females was greater. The prevalence of recurrence in females compared to males was more common. Also, hospital readmission between sex groups was the same. There is uncertainty about long‐term immunity after SARS‐Cov‐2 infection. Thus, the possibility of reinfection and recurrence after recovery is not unexpected. In addition, there is a probability of hospital readmission due to adverse events of COVID‐19 after discharge. However, with mass vaccination of people and using the principles of prevention and appropriate management of the disease, frequent occurrence of the disease can be controlled. The SARS-Cov-2 pandemic has recently appeared as a global threat to human health. 1 It has forced many countries to take unprecedented steps to prevent it from spreading and has imposed high costs on the health care sector of countries. 2 Up to August 9, 2021 , the World Health Organization (WHO) has approved about 202 million confirmed cases, with nearly 4300 million deaths and 4 billion doses of vaccine have been administered. 3 Most COVID-19 patients have experienced mild to moderate symptoms and recovered without requiring special treatment. Mild-type infected individuals experience fever, cough, sore throat, diarrhea, headaches, myalgia or arthralgia, exhaustion, and loss of sense of smell and taste. 4, 5 The symptoms of COVID-19 pneumonia include dyspnea, loss of appetite, dizziness, pain or pressure in the chest, and fever (above 38°C). Older people and those with underlying medical problems such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer will probably experience more severe complications. 6 The increase in the liver enzyme and the low number of lymphocytes with an increase in CRP (C-reactive protein) is often present in COVID-19 patients. 7 It can eventually lead to acute respiratory distress syndrome (ARDS) and death. 8, 9 The COVID-19 virus spreads mainly through saliva or sprays from the nose; the best way to prevent and reduce transmission speed is adequate awareness of the COVID-19 viruses and how it spreads. By washing hands or using alcohol and not touching the face, one can protect himself and others against infection. Being infected with the virus does not produce permanent immunity and antibody against the virus in all people. 10 More than 90% of individuals infected with SARS-Cov-2 produce antibodies about a week after starting the symptoms, which lasts for at least 3 months. 11, 12 There is an urgent need to understand better whether those who have recovered from COVID -19 are secure to reinfection or not. The effectiveness of vaccination strategies, concerns for herd immunity, and general modeling for the epidemic depend on the effectiveness and period of immunity versus COVID-19. The acute respiratory syndrome of the coronavirus 2 (SARS-Cov-2) has already produced distinct immunity responses. However, the rate and time of immunity in infected individuals against reinfection are not clarified. 13 Immunity after infection may be created with immune responses of IgG antibodies and mediated by specialized T cells. Primary considerations when examining the immunity of postinfection include identifying protective functions, identifying measurable biological markers, and the precise definition of reinfection, recurrence, and readmission, death, or transfer to other people. 14, 15 The exact cause of the disease recurrence of some COVID-19 patients is unclear. It was previously mentioned that imperfect eradication of the virus from the tissues was the cause. Another notion says that inadequate antibodies or the rapid disappearance of these antibodies due to a stimulus factor are the cause. 15 Short-period immunity against reinfection has been observed in non-human models of SARS-Cov-2. 12 Reinfection and possible hospital readmission is a significant and costly problem in the pandemic. 16 In addition, the rotation and dynamics of the virus and its mutation in the countries lead to resistance to treatment and vaccinations. 17 Trying to accurately define and monitor the rate of reinfection, recurrence, readmission, and affecting factors can provide practical strategies for policy-making to prevent reinfection, improve health care, and treat patients. According to the past reports, the frequency of readmission was reported as between 2% and 5%. Readmission is usually in the first week after clearance. It may be due to other underlying diseases except for reinfection. 18 The reinfection rate in different countries has been reported between less than 0.5% to more than 5%. 19, 20 Thus, according to the various reports about the probability of reinfection, recurrence, or hospital readmission due to COVID-19 in the whole world, we decided to design a study with the purpose of de- OR (Readmission*[Mesh] OR "hospital readmission")). The inclusion criteria were as follows: (1) the studies were published in English; (2) peer-reviewed and published articles included desired indicators and definitions. The exclusion criteria were as follows: (1) duplicate articles that refer to publishing the same intellectual material more than once, by the author or publisher and (2) gray literature such as non-peer-reviewed dissertations, government reports, conference proceedings/papers, statements by professional organizations, and so forth. We included studies based on PRISMA guidelines for performing the standard meta-analysis techniques. After retrieving articles from the mentioned databases and eliminating duplicate articles, two authors conducted the screening process and data collection independently based on inclusion criteria. The following information was extracted from the selected studies: the first author's name, country of origin, study design, sample size, age, sex, diagnostic criteria of 2019-nCoV, type of index (recurrence, reinfection, readmission), frequency of indices, time of occurrence from discharge, clinical signs and symptoms, comorbidity, disease severity, and outcome of disease (recovered or death). The quality check process was performed by two reviewers that assessed the quality of data in included studies. We used the STROBE checklist to ensure the quality of selected observational studies. After a full-text quality assessment of selected studies, studies with high and medium quality were included in the analyses and finally, the key findings were extracted. The "metaprop" command was used to perform fixed or randomeffects meta-analysis in STATA. Random forest was used to show the results. The between-study heterogeneity was assessed using a χ 2 -test-based Cochran's Q statistic test at p < 0.05 and I 2 greater than 50%. A fixed-effect model was used based on p value ≥ 0.05 or I 2 lower than 50%, and a random-effect model was used based on p value < 0.05 or I 2 greater than 50%, finally pooled estimates in meta-analyses were estimated with a 95% confidence interval. In some studies, the denominator of the fraction could not be extracted to calculate the frequency of gender in patients. To avoid overestimation and to avoid ignoring studies with high sample size, based on the results of other studies, the average frequency of women with the COVID-19 was considered as 47% and calculations of missed data were made based on this frequency ( Table 1 ). All of the analyses were conducted with Stata packages (version 14). After assessing the quality of selected studies, 25 observational studies were included in the analysis ( Figure 1 ). The majority of studies were conducted in China. Details of the selected studies and their characteristics have been shown in Table 1 . The description of eligible studies reporting the frequency of reinfection, recurrence, and readmission among COVID-19 patients The patients with reinfection ranged in age from 15 to 99 years old. [23] [24] [25] [26] [27] According to the reports of COVID-19 reinfection cases in studies, most of them were detected based on RT-PCR test using nasopharyngeal swab specimens. [23] [24] [25] [26] [27] However, in other studies, in addition to the PCR test, chemiluminescent microparticle immunoassay for anti-SARS-Cov-2 antibodies was also used. 23 and the other 72-year-old woman with a history of rhabdomyolysis and acute vascular occlusion that the main cause of her death was not due to a reinfection with SARS-Cov-2. 24 The underlying diseases among reinfected patients were not prevalent. [23] [24] [25] But the most common were diabetes and immune system deficiencies such as HIV and the use of immunosuppressive drugs due to certain diseases. 26, 27 Based on the results of Table 2 , the overall prevalence of reinfection among COVID-19 patients was 3 (95% CI 0.8-5) per 1000 patients. In these studies, there was heterogeneity in the prevalence of reinfection (I 2 92.08%, p < 0.001) ( Figure 2 ). After assessing the prevalence of reinfection based on sex groups, it was observed that in males compared to females, reinfection was more common (3.2 vs. "Recurrence" or "Recrudescence" or "Relapse" or "Reactivation" is the manifestation of symptoms after recovery. 21 In COVID-19, based on the literature, the meaning of recurrence is referred to infection with the same species and strain of SARS-Cov-2 that may occur due to immunodeficiency of the host. 28 The patients with COVID-19 recurrence evidence ranged in age from 4 to 80 years old. [30] [31] [32] [33] [34] [35] [36] [37] [38] Most of them were detected based on RT-PCR tests using anal or nasopharyngeal swab specimens. [30] [31] [32] [33] [34] [35] [36] [37] [38] Some of them were detected using CT scan and chemiluminescent microparticle immunoassay for anti-SARS-Cov-2 antibodies, too. [30] [31] [32] [35] [36] [37] [38] The minimum and maximum time of recurrence onset from first discharge were reported from 7 to 47 days with an average of 17.25 days. 33 Most of the COVID-19 recurrent cases were asymptomatic or with mild-to-moderate symptoms that recovered. 30 per 1000 patients. There was heterogeneity in the prevalence of readmission (I 2 97.41%, p < 0.001) (Figure 4) . After comparing the readmission between sex, groups were observed in that readmission among males and females was the same (70 in 1000 patients) ( can affect the estimated rate of reinfection and recurrence. After comparing the basic characteristics of patients between indices, the rate of reinfection in females was lower than in males. In contrast, the rate of recurrence in males was lower than in females. In addition, the result of the systematic review by Piri et al. 50 indicates that among all patients that had a recurrence, 47 Our study has specific strengths and limitations. One of the strengths of the current study is that this is the first study that considers the impact of definitions in the estimates of reinfections in patients with SARS-Cov-2. This can make a better viewpoint in health care decisions. One important limitation is that only peer-reviewed articles in the English language were included in the current study, which can make a bias in the interpretation of results. Also, all of the understudied populations in the articles were COVID-19 patients who were monitored for indices after hospitalization and discharge. Thus, mild cases and outpatients during initial infection have not been studied actively for probable reinfection, recurrence, or hospital readmission. Therefore, it seems that the results of the current metaanalysis can be generalized to inpatients and it cannot depict the status of the general population. Considering that there is uncertainty about long-term immunity after SARS-Cov-2 infection, the possibility of reinfection and recurrence after recovery is not unexpected. In addition, there is a probability of hospital readmission due to adverse events of COVID-19 after discharge. It is better to prevent underestimation or false overestimation by active surveillance and case finding, creating proper definitions, and using high-accuracy diagnostic tests. Moreover, these indices should be reported more carefully. This study was supported by the School of Public Health and Safety, Shahid Beheshti University of Medical Sciences grant number 27960. The funding agency did not play any role in the planning, conduct, and reporting or in the decision to submit the paper for publication. The emergence of a novel coronavirus causing respiratory illness from Wuhan Another decade COVID-19) Gastrointestinal symptoms and coronavirus disease 2019: a case-control study from the United States Isolated severe thrombocytopenia in a patient with COVID-19: a case report Early transmission dynamics in Wuhan, China, of novel coronavirus-infected The coronavirus disease 2019 (COVID-19) in children: a study in an Iranian Children's Referral Hospital COVID-19 induced hepatitis B virus reactivation: a novel case from the United Arab Emirates Symmetrical polyneuropathy in coronavirus disease 2019 (COVID-19) Effective strategies to prevent coronavirus disease-2019 (COVID-19) outbreak in hospital Robust neutralizing antibodies to SARS-CoV-2 infection persist for months Spread of SARS-CoV-2 in the Icelandic Population Current meta-analysis does not support the possibility of COVID-19 re-infections Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19 Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections Why do patients keep coming back? Results of a re-admitted patient survey Experimental and in silico evidence suggests vaccines are unlikely to be affected by D614G mutation in SARS-CoV-2 spike protein Hospital readmissions of discharged patients with COVID-19 SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). The Lancet Clinical course and risk factors for recurrence of positive SARS-CoV-2 RNA: a retrospective cohort study from Wuhan Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR).2020. Accessed Assessment of the risk of SARS-CoV-2 re-infection in an intense re-exposure setting SARS-CoV-2 re-infection risk in Austria Prior COVID-19 significantly reduces the risk of subsequent infection, but re-infections are seen after eight months Case Reports of COVID 19 Recurrence Suspected recurrent SARS-CoV-2 infections among residents of a skilled nursing facility during a second COVID-19 outbreak-Kentucky A case series describing the recurrence of COVID-19 in patients who recovered from initial illness in Bangladesh Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case Clinical characteristics of recovered COVID-19 patients with re-detectable positive RNA test Clinical features of COVID-19 convalescent patients with re-positive nucleic acid detection immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR The treatment and followup of 'recurrence' with discharged COVID-19 patients: data from Guizhou Epidemiological and clinical findings of short-term recurrence of severe acute respiratory syndrome coronavirus 2 ribonucleic acid polymerase chain reaction positivity in 1282 discharged coronavirus disease 2019 cases: a multicenter, retrospective, observational study Incidence, clinical course and risk factor for recurrent PCR positivity in discharged COVID-19 patients in Guangzhou, China: a prospective cohort study Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a populationbased observational cohort study Characteristics of recovered COVID-19 patients with recurrent positive RT-PCR findings in Wuhan, China: a retrospective study Readmissions among patients with COVID-19 assessment of thirty-day readmission rate, timing, causes and predictors after hospitalization with COVID-19 Characteristics of hospitalized COVID-19 patients discharged and experiencing same-hospital readmission-United States Positive result of Sars-Cov-2 in faeces and sputum from discharged patients with COVID-19 in Yiwu The clinical characteristic of eight patients of COVID-19 with positive RT-PCR test after discharge study of fifteen COVID-19 patients with positive RT-PCR retest results after discharge Analysis of risk factors on readmission cases of COVID-19 in the Republic of Korea: using nationwide health claims data Thirty-day readmission rate of COVID-19 patients discharged from a tertiary care university hospital in Turkey: an observational, single-center study Atypical presentations of coronavirus disease 2019 (COVID-19) from onset to readmission Hospital readmissions after implementation of a discharge care program for patients with COVID-19 illness A systematic review and meta-analysis of discharged COVID-19 patients retesting positive for RT-PCR A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations Reinfection risk of novel coronavirus (CoVID-19): a systematic review of current evidence Nebehay S WHO is investigating reports of recovered COVID patients testing positive again False-negative results of initial RT-PCR assays for COVID-19: a systematic review Recurrence of positive SARS-CoV-2 in patients recovered from COVID-19 Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: A single-hospital experience in Clinical characteristics associated with long-term viral shedding in patients with coronavirus disease 2019 Differences of severe acute respiratory syndrome coronavirus 2 shedding duration in sputum and nasopharyngeal swab specimens among adult inpatients with coronavirus disease 2019 Sex and gender differences in the outcome of patients with COVID-19 Recurrent SARS-CoV-2 RNA positivity after COVID-19: a systematic review and metaanalysis Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis The authors would like to thank the School of Public Health and Sciences for technically supporting this study. The authors declare that there are no conflict of interests. The data that support the findings of this study are available from the corresponding author upon reasonable request. https://orcid.org/0000-0001- Niloufar